BAIT
SLFN11
SLFN8/9
schlafen family member 11
GO Process (2)
GO Function (1)
GO Component (4)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Homo sapiens
PREY
PPP2R1A
PP2A-Aalpha, PP2AAALPHA, PR65A
protein phosphatase 2, regulatory subunit A, alpha
GO Process (25)
GO Function (4)
GO Component (8)
Gene Ontology Biological Process
- G2/M transition of mitotic cell cycle [TAS]
- RNA metabolic process [TAS]
- RNA splicing [NAS]
- apoptotic process [TAS]
- ceramide metabolic process [NAS]
- chromosome segregation [IDA]
- fibroblast growth factor receptor signaling pathway [TAS]
- gene expression [TAS]
- inactivation of MAPK activity [NAS]
- mRNA metabolic process [TAS]
- mitotic cell cycle [TAS]
- mitotic nuclear envelope reassembly [TAS]
- negative regulation of cell growth [NAS]
- negative regulation of tyrosine phosphorylation of Stat3 protein [NAS]
- nuclear-transcribed mRNA catabolic process, nonsense-mediated decay [TAS]
- protein complex assembly [TAS]
- protein dephosphorylation [TAS]
- regulation of DNA replication [NAS]
- regulation of Wnt signaling pathway [NAS]
- regulation of cell adhesion [NAS]
- regulation of cell differentiation [NAS]
- regulation of growth [NAS]
- regulation of transcription, DNA-templated [NAS]
- response to organic substance [NAS]
- second-messenger-mediated signaling [NAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Proximity Label-MS
An interaction is inferred when a bait-enzyme fusion protein selectively modifies a vicinal protein with a diffusible reactive product, followed by affinity capture of the modified protein and identification by mass spectrometric methods.
Publication
SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243.
Schlafen11 (SLFN11) inactivation occurs in approximately 50% of cancer cell lines and in a large fraction of patient tumor samples, which leads to chemoresistance. Therefore, new therapeutic approaches are needed to target SLFN11-deficient cancers. To that effect, we conducted a drug screen with the NCATS mechanistic drug library of 1,978 compounds in isogenic SLFN11-knockout (KO) and wild-type (WT) leukemia cell ... [more]
Cancer Res Dec. 01, 2020; 81(11);3067-3078 [Pubmed: 33863777]
Throughput
- High Throughput
Curated By
- BioGRID